Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361952745> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4361952745 abstract "<div>AbstractPurpose:<p>Apoptotic dysregulation, redox adaptive mechanisms, and resilience to hypoxia are major causes of glioblastoma (GBM) resistance to therapy. Commonly known as crucial factors in energy metabolism, OCTN2 (SLC22A5) and its substrate <i>L</i>-carnitine (LC) are increasingly recognized as actors in cytoprotection. This study provides a comprehensive expression and survival analysis of the OCTN2/LC system in GBM and clarifies the system's impact on GBM progression.</p>Experimental Design:<p>OCTN2 expression and LC content were measured in 121 resected human GBM specimens and 10 healthy brain samples and analyzed for prognostic significance. Depending on LC administration, the effects of hypoxic, metabolic, and cytotoxic stress on survival and migration of LN18 GBM cells were further studied <i>in vitro</i>. Finally, an orthotopic mouse model was employed to investigate inhibition of the OCTN2/LC system on <i>in vivo</i> GBM growth.</p>Results:<p>Compared with healthy brain, OCTN2 expression was increased in primary and even more so in recurrent GBM on mRNA and protein level. High OCTN2 expression was associated with a poor overall patient survival; the unadjusted HR for death was 2.7 (95% CI, 1.47–4.91; <i>P</i> < 0.001). LC administration to GBM cells increased their tolerance toward cytotoxicity, whereas siRNA-mediated OCTN2 silencing led to a loss of tumor cell viability. In line herewith, OCTN2/LC inhibition by meldonium resulted in reduced tumor growth in an orthotopic GBM mouse model.</p>Conclusions:<p>Our data indicate a potential role of the OCTN2/LC system in GBM progression and resistance to therapy, and suggests OCTN2 as a prognostic marker in patients with primary GBM.</p></div>" @default.
- W4361952745 created "2023-04-05" @default.
- W4361952745 creator A5022153571 @default.
- W4361952745 creator A5036918588 @default.
- W4361952745 creator A5054013279 @default.
- W4361952745 creator A5054419705 @default.
- W4361952745 creator A5056236835 @default.
- W4361952745 creator A5062256782 @default.
- W4361952745 creator A5063434903 @default.
- W4361952745 creator A5078433431 @default.
- W4361952745 creator A5082933290 @default.
- W4361952745 creator A5088228708 @default.
- W4361952745 creator A5090443193 @default.
- W4361952745 date "2023-03-31" @default.
- W4361952745 modified "2023-10-16" @default.
- W4361952745 title "Data from <i>L</i>-Carnitine–Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme" @default.
- W4361952745 doi "https://doi.org/10.1158/1078-0432.c.6527738.v1" @default.
- W4361952745 hasPublicationYear "2023" @default.
- W4361952745 type Work @default.
- W4361952745 citedByCount "0" @default.
- W4361952745 crossrefType "posted-content" @default.
- W4361952745 hasAuthorship W4361952745A5022153571 @default.
- W4361952745 hasAuthorship W4361952745A5036918588 @default.
- W4361952745 hasAuthorship W4361952745A5054013279 @default.
- W4361952745 hasAuthorship W4361952745A5054419705 @default.
- W4361952745 hasAuthorship W4361952745A5056236835 @default.
- W4361952745 hasAuthorship W4361952745A5062256782 @default.
- W4361952745 hasAuthorship W4361952745A5063434903 @default.
- W4361952745 hasAuthorship W4361952745A5078433431 @default.
- W4361952745 hasAuthorship W4361952745A5082933290 @default.
- W4361952745 hasAuthorship W4361952745A5088228708 @default.
- W4361952745 hasAuthorship W4361952745A5090443193 @default.
- W4361952745 hasBestOaLocation W43619527452 @default.
- W4361952745 hasConcept C104317684 @default.
- W4361952745 hasConcept C119056186 @default.
- W4361952745 hasConcept C127561419 @default.
- W4361952745 hasConcept C134018914 @default.
- W4361952745 hasConcept C150903083 @default.
- W4361952745 hasConcept C190283241 @default.
- W4361952745 hasConcept C207001950 @default.
- W4361952745 hasConcept C2778435403 @default.
- W4361952745 hasConcept C2780967304 @default.
- W4361952745 hasConcept C31573885 @default.
- W4361952745 hasConcept C502942594 @default.
- W4361952745 hasConcept C54355233 @default.
- W4361952745 hasConcept C55493867 @default.
- W4361952745 hasConcept C81885089 @default.
- W4361952745 hasConcept C86803240 @default.
- W4361952745 hasConceptScore W4361952745C104317684 @default.
- W4361952745 hasConceptScore W4361952745C119056186 @default.
- W4361952745 hasConceptScore W4361952745C127561419 @default.
- W4361952745 hasConceptScore W4361952745C134018914 @default.
- W4361952745 hasConceptScore W4361952745C150903083 @default.
- W4361952745 hasConceptScore W4361952745C190283241 @default.
- W4361952745 hasConceptScore W4361952745C207001950 @default.
- W4361952745 hasConceptScore W4361952745C2778435403 @default.
- W4361952745 hasConceptScore W4361952745C2780967304 @default.
- W4361952745 hasConceptScore W4361952745C31573885 @default.
- W4361952745 hasConceptScore W4361952745C502942594 @default.
- W4361952745 hasConceptScore W4361952745C54355233 @default.
- W4361952745 hasConceptScore W4361952745C55493867 @default.
- W4361952745 hasConceptScore W4361952745C81885089 @default.
- W4361952745 hasConceptScore W4361952745C86803240 @default.
- W4361952745 hasLocation W43619527451 @default.
- W4361952745 hasLocation W43619527452 @default.
- W4361952745 hasOpenAccess W4361952745 @default.
- W4361952745 hasPrimaryLocation W43619527451 @default.
- W4361952745 hasRelatedWork W1733348976 @default.
- W4361952745 hasRelatedWork W1999992556 @default.
- W4361952745 hasRelatedWork W2017337406 @default.
- W4361952745 hasRelatedWork W2025438595 @default.
- W4361952745 hasRelatedWork W2062908963 @default.
- W4361952745 hasRelatedWork W2069300823 @default.
- W4361952745 hasRelatedWork W2131274358 @default.
- W4361952745 hasRelatedWork W2370342628 @default.
- W4361952745 hasRelatedWork W2475187007 @default.
- W4361952745 hasRelatedWork W2604918044 @default.
- W4361952745 isParatext "false" @default.
- W4361952745 isRetracted "false" @default.
- W4361952745 workType "article" @default.